VUNO has expanded the coverage of its non-reimbursable VUNO Med–DeepCARS, an artificial intelligence (AI)-based cardiac arrest prediction software, to include children under 19 years old.

The decision, made by the National Evidence-based Healthcare Collaborating Agency (NECA) on Thursday, broadens the non-reimbursed coverage of VUNO Med–DeepCARS to encompass patients of all ages.

VUNO Med-DeepCARS analyzes blood pressure, pulse, respiration, and temperature, which are registered in electronic medical records (EMR) to provide a score for a patient's risk of cardiac arrest.

This enables proactive response by physicians in general wards where it is difficult to constantly monitor all hospitalized patients. A confirmatory clinical trial study demonstrated its efficacy without any restrictions on patient age, gender, or medical specialty.

VUNO anticipates that the extended use of its device will help address the shortage of medical personnel in the pediatric department and reduce the occurrence of unexpected cardiac arrests within hospitals.

"The expansion of non-payment coverage for VUNO Med–DeepCARS is significant in that it will help to ensure the safety of more patients regardless of age and help fill the personnel shortage in the medical field," VUNO CEO Lee Ye-ha said. "As the product continues to prove its marketability in terms of business performance, we will continue to strive to make it active in more clinical sites, including the U.S."

VUNO's Q2 sales surge over 300% year-on-year

VUNO reported consolidated revenue of 3 billion won ($2.2 million) for the second quarter, up 385 percent compared to the same period last year, thanks to sales generated from VUNO Med–DeepCARS.

The product alone generated approximately 1.9 billion won in revenue in the second quarter, an increase of around 60 percent from the previous quarter.

The device, which receives payment whenever it is used in the field, is rapidly being adopted in the Korean medical field,

The company projects that it could secure contracts with 40 hospitals in the third quarter, surpassing its initial year-end target.

VUNO is also accelerating its plans to expand the device into the U.S. market as it won an innovative medical device designation from the U.S. FDA in June.

The company is conducting clinical studies with U.S. medical institutions and has registered local patents for its core technology.